血管内皮生长因子（VEGF）特异性抗体贝伐单抗在人类直肠癌中具有抗血管生成作用的直接证据。
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
作者信息
Willett Christopher G, Boucher Yves, di Tomaso Emmanuelle, Duda Dan G, Munn Lance L, Tong Ricky T, Chung Daniel C, Sahani Dushyant V, Kalva Sanjeeva P, Kozin Sergey V, Mino Mari, Cohen Kenneth S, Scadden David T, Hartford Alan C, Fischman Alan J, Clark Jeffrey W, Ryan David P, Zhu Andrew X, Blaszkowsky Lawrence S, Chen Helen X, Shellito Paul C, Lauwers Gregory Y, Jain Rakesh K
机构信息
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
出版信息
Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25.
Abstract
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.
摘要
血管内皮生长因子（VEGF）阻断对人类肿瘤血管生物学的影响尚不清楚。在此我们表明，单次输注VEGF特异性抗体贝伐单抗可降低直肠癌患者的肿瘤灌注、血管容积、微血管密度、间质液压力以及存活的循环内皮细胞和祖细胞数量，并增加有周细胞覆盖的血管比例。这些数据表明，VEGF阻断在人类肿瘤中具有直接且快速的抗血管作用。
相似文献
1
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.血管内皮生长因子（VEGF）特异性抗体贝伐单抗在人类直肠癌中具有抗血管生成作用的直接证据。
Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25.
2
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.直接证据表明，抗血管内皮生长因子（VEGF）抗体贝伐单抗可上调直肠癌患者肿瘤中的基质细胞衍生因子1α（SDF1α）、CXC趋化因子受体4（CXCR4）、CXC趋化因子配体6（CXCL6）和神经纤毛蛋白1。
Cancer Res. 2009 Oct 15;69(20):7905-10. doi: 10.1158/0008-5472.CAN-09-2099. Epub 2009 Oct 13.
3
Vascular biology support for the use of bevacizumab in colorectal cancer.贝伐单抗用于结直肠癌的血管生物学支持。
Expert Opin Investig Drugs. 2004 Jun;13(6):703-5. doi: 10.1517/13543784.13.6.703.
4
Technology evaluation: bevacizumab, Genentech/Roche.技术评估：贝伐单抗，基因泰克/罗氏公司。
Curr Opin Mol Ther. 2003 Dec;5(6):657-67.
5
Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.将鼠源等效的贝伐单抗（阿瓦斯汀）（一种抗血管内皮生长因子单克隆抗体）进行基因传递，以抑制免疫缺陷小鼠体内人类肿瘤的生长。
Hum Gene Ther. 2008 Mar;19(3):300-10. doi: 10.1089/hum.2007.109.
6
Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging.使用功能CT成像评估贝伐单抗抗VEGF单克隆抗体对结直肠癌的早期抗血管作用。
Am J Clin Oncol. 2007 Jun;30(3):315-8. doi: 10.1097/01.coc.0000258119.90805.ca.
7
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.晚期直肠癌对贝伐单抗及放化疗的完全病理缓解
Nat Clin Pract Oncol. 2007 May;4(5):316-21. doi: 10.1038/ncponc0813.
8
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.双特异性血管生成素-2-血管内皮生长因子-A抗体的急性肿瘤反应：多参数磁共振成像和基因表达谱分析的见解
Br J Cancer. 2016 Sep 6;115(6):691-702. doi: 10.1038/bjc.2016.236. Epub 2016 Aug 16.
9
Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease.抗血管内皮生长因子（VEGF）药物贝伐单抗用于克罗恩病患者的可行性。
Inflamm Bowel Dis. 2011 Jul;17(7):1632. doi: 10.1002/ibd.21545. Epub 2010 Nov 15.
10
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.定量抗血管内皮生长因子单克隆抗体的抗血管生成作用：来自成像技术的见解
Clin Cancer Res. 2009 Nov 1;15(21):6674-82. doi: 10.1158/1078-0432.CCR-09-0731. Epub 2009 Oct 27.
引用本文的文献
1
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy.深入了解与三级淋巴结构相关的肿瘤浸润性基质细胞及其在癌症免疫治疗中的潜在功能。
Exp Hematol Oncol. 2025 Aug 10;14(1):105. doi: 10.1186/s40164-025-00695-8.
2
How Can We Improve the Tumor Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer?我们如何提高局部晚期直肠癌对术前放化疗的肿瘤反应？
Ewha Med J. 2023 Dec;46(Suppl 1):e25. doi: 10.12771/emj.2023.e25. Epub 2023 Dec 31.
3
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy.肿瘤相关血管在T细胞归巢与免疫中的作用：癌症治疗的机遇
Nat Rev Immunol. 2025 Jun 27. doi: 10.1038/s41577-025-01187-w.
4
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.雷莫西尤单抗难治性晚期胃癌患者中雷莫西尤单抗进展后联合伊立替康的随机III期试验：RINDBeRG试验
J Clin Oncol. 2025 Jul;43(19):2196-2207. doi: 10.1200/JCO.24.01119. Epub 2025 May 23.
5
Research hotspots and emerging trends in targeted therapy for colorectal cancer: a bibliometric analysis (2000-2023).结直肠癌靶向治疗的研究热点与新趋势：一项文献计量分析（2000 - 2023年）
Discov Oncol. 2025 May 16;16(1):789. doi: 10.1007/s12672-025-02632-x.
6
Targeting tumor angiogenesis and metabolism with photodynamic nanomedicine.用光动力纳米药物靶向肿瘤血管生成与代谢。
Front Cell Dev Biol. 2025 Apr 1;13:1558393. doi: 10.3389/fcell.2025.1558393. eCollection 2025.
7
Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption.抗血管内皮生长因子A抗体和舒尼替尼在大鼠骨吸收模型中的轻度抗骨吸收活性。
Bone Rep. 2025 Mar 17;25:101837. doi: 10.1016/j.bonr.2025.101837. eCollection 2025 Jun.
8
Transforming Cancer Therapy: Unlocking the Potential of Targeting Vascular and Stromal Cells in the Tumor Microenvironment.变革癌症治疗：挖掘肿瘤微环境中靶向血管和基质细胞的潜力
Cancer Res. 2025 Apr 2. doi: 10.1158/0008-5472.CAN-24-4744.
9
Analysis of Bevacizumab-Induced Gastrointestinal Perforation Using the Japanese Adverse Drug Event Report Database.利用日本药品不良反应报告数据库分析贝伐单抗所致胃肠道穿孔
Cureus. 2025 Feb 5;17(2):e78585. doi: 10.7759/cureus.78585. eCollection 2025 Feb.
10
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.阿替利珠单抗与贝伐单抗联合治疗人乳头瘤病毒阳性不可切除或转移性肛管鳞状细胞癌的II期试验
Clin Cancer Res. 2025 May 1;31(9):1657-1666. doi: 10.1158/1078-0432.CCR-24-1512.
本文引用的文献
1
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.一项关于抗血管内皮生长因子抗体贝伐单抗用于转移性肾癌的随机试验。
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
2
Antiangiogenesis drug promising for metastatic colorectal cancer.抗血管生成药物对转移性结直肠癌有前景。
Lancet. 2003 Jun 7;361(9373):1959. doi: 10.1016/S0140-6736(03)13603-3.
3
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.抗血管内皮生长因子治疗对CPT-11瘤内摄取的影响。
Br J Cancer. 2003 Jun 16;88(12):1979-86. doi: 10.1038/sj.bjc.6601005.
4
Molecular regulation of vessel maturation.血管成熟的分子调控
Nat Med. 2003 Jun;9(6):685-93. doi: 10.1038/nm0603-685.
5
The biology of VEGF and its receptors.血管内皮生长因子（VEGF）及其受体的生物学特性
Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669.
6
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?血管和造血干细胞：抗血管生成治疗的新靶点？
Nat Rev Cancer. 2002 Nov;2(11):826-35. doi: 10.1038/nrc925.
7
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.血管通透性因子/血管内皮生长因子：肿瘤血管生成中的关键细胞因子及诊断与治疗的潜在靶点。
J Clin Oncol. 2002 Nov 1;20(21):4368-80. doi: 10.1200/JCO.2002.10.088.
8
Clinical translation of angiogenesis inhibitors.血管生成抑制剂的临床转化
Nat Rev Cancer. 2002 Oct;2(10):727-39. doi: 10.1038/nrc905.
9
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.用抗血管生成疗法使肿瘤血管正常化：联合治疗的新范例。
Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.
Zotero 插件